Erythropoiesis-stimulating agents (ESAs) + Luspatercept + Lenalidomide + Hypomethylating agents (HMAs) + Reb blood cell transfusion

Pre-clinicalActive

1 views this week 0 watching💤 Quiet

Interest: 30/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Lower-risk Myelodysplastic Syndromes (TD LR-MDS)

Conditions

Lower-risk Myelodysplastic Syndromes (TD LR-MDS)

Trial Timeline

Feb 2, 2026 → May 31, 2026

NCT ID

NCT07465029

About Erythropoiesis-stimulating agents (ESAs) + Luspatercept + Lenalidomide + Hypomethylating agents (HMAs) + Reb blood cell transfusion

Erythropoiesis-stimulating agents (ESAs) + Luspatercept + Lenalidomide + Hypomethylating agents (HMAs) + Reb blood cell transfusion is a pre-clinical stage product being developed by Bristol Myers Squibb for Lower-risk Myelodysplastic Syndromes (TD LR-MDS). The current trial status is active. This product is registered under clinical trial identifier NCT07465029. Target conditions include Lower-risk Myelodysplastic Syndromes (TD LR-MDS).

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07465029	Pre-clinical	Active	Feb 2, 2026	May 31, 2026	Lower-risk Myelodysplastic Syndromes (TD LR-MDS)

Competing Products

1 competing product in Lower-risk Myelodysplastic Syndromes (TD LR-MDS)

See all competitors

Product	Company	Stage	Hype Score
JSP191	Jasper Therapeutics	Phase 1	11